E2F3 and prostate carcinoma: In addition to the above cancers, C. minima can also be used in the treatment of prostate cancer, osteosarcoma, gastric cancer, etc. You P et al. [69] found that Brevilin A in C. minima inhibited prostate cancer cell proliferation, migration and invasion, suppressed the expression of lncRNA H19 and E2F3, and enhanced the level of miR-194.